Active recording of adverse events after COVID-19 vaccination

Active recording of adverse events after COVID-19 vaccination - CoVaKo

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025373

Enrollment

30000

Registered

2021-05-21

Start date

2021-05-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vaccination

Interventions

Group 1: BNT162b2 (BioNTech/Pfizer) (homologous) Group 2: ChadOx1 (AstraZeneca) (homologous) Group 3: mRNA-1273 (Moderna) (homologous) Group 4: ChadOx1 (AstraZeneca) + (mRNA-1273 oder BNT162b2) (heter

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: COVID-19 vaccination or controll vaccination

Exclusion criteria

Exclusion criteria: none of the above named vaccines

Design outcomes

Primary

Measure	Time frame
Frequency of adverse events after COVID-19 vaccination and control vaccinations that resulted in physician visits and/or hospitalizations within 18 weeks.	—

Secondary

Measure	Time frame
General occurrence of post-vaccination symptoms of any severity within the first two weeks after vaccination (for COVID-19 vaccination after 1st or 2nd dose).	—

Countries

Germany

Contacts

Public ContactMaria Sebastiao

Universitätsklinikum Erlangen, Allgemeinmedizinisches Institut

Maria.Sebastiao@uk-erlangen.de+49 (09131) 85-45761

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 11, 2026